Search PubMed⌕ Search

Biomedical subjects

P Liberini

Publications and source records attributed to P Liberini.

At least 37 records · Page 2Linked to original sources
PubMed1994

Encapsulated genetically engineered fibroblasts: release of nerve growth factor and effects in vivo on recovery of cholinergic markers after devascularizing cortical lesions.

Genetically engineered rat fibroblasts producing nerve growth factor (NGF) were encapsulated in alginate-polylysine-alginate gels with the objective to produce viable "minifactories" continuously producing and secreting NGF into the rat brain. Microencapsulated fibroblasts (NGF secretors and NGF non-secretors) were placed onto the surface of the lesioned rat cortex (unilateral devascularizing lesion) and animals were sacrificed 30 days after surgery. Fibroblasts NGF-non secreters normally produce tumors after implantation, therefore, they were irradiated prior to encapsulation. Three other experimental groups were studied in parallel: non-lesioned (controls), lesioned rats receiving "empty" alginate spheres and lesioned animals without treatment and microspheres. Biochemical analysis of microdissected brain tissues of lesioned animals treated with encapsulated NGF-secretor fibroblasts showed a significant increase in choline acetyltransferase (ChAT) activity in cortices adjacent to the lesion but not far from it (entorhinal cortex). This may indicate a gradient of concentration of the released NGF and/or differential responsivity of lesioned vs non-lesioned target tissue. ChAT enzymatic activity in the microdissected nucleus basalis magnocellularis (NBM) was significantly decreased (P < 0.05) in all lesioned animals treated with spheres without fibroblasts and those with fibroblasts not secreting NGF. Morphometric analysis of ChAT-IR and low affinity NGF-receptor IR cholinergic neurons in the middle portion of the NBM shows a prevention of neuronal shrinkage and extensive neuropil in animals treated with microencapsulated NGF-secretor fibroblasts. The results of this study demonstrate that NGF from encapsulated genetically engineered fibroblasts can be secreted for at least long enough to prevent degenerative changes of cholinergic neurons in the NBM.

Alginates↗
PubMed1993

Alz-50 immunoreactivity in the central nervous system of adult rat and primate.

The purpose of this work was to investigate the distribution and density of Alz-50 immunoreactivity in the central nervous system of normal adult and cortically injured rats and primates (Cercopithecus aethiops). In control animals of both species a consistent pattern of fiber immunoreactivity was detected within the hypothalamus (arcuate nucleus and median eminence) and the spinal cord (posterior horn and dorsal root nerve). Immunoreactive perikarya were predominantly observed throughout the anterior region of the third ventricle. An identical localization and density of Alz-50 staining was observed in lesioned animals. These experiments reveal that the pattern of Alz-50 immunoreactivity is not affected by the neurodegenerative processes that follow the cortical devascularizing lesion. These observations suggest that the monoclonal antibody Alz-50, besides recognizing cytoskeletal components in degenerating neurons, reacts with specific epitopes located in the hypothalamus and spinal cord of normal mammalian central nervous system.

Animals↗
PubMed1993

Long-term protective effects of human recombinant nerve growth factor and monosialoganglioside GM1 treatment on primate nucleus basalis cholinergic neurons after neocortical infarction.

Neocortical infarction induces biochemical and morphological retrograde degenerative changes in cholinergic neurons of the rat nucleus basalis magnocellularis [Sofroniew et al. (1983) Brain Res. 289, 370-374]. In the present study, this lesion model has been reproduced in the non-human primate (Cercopithecus aethiops) to investigate whether degenerative changes affecting the cortex surrounding the lesioned area and the ipsilateral basal forebrain are prevented by the early administration of recombinant human nerve growth factor alone or in combination with the monosialoganglioside GM1. Six months after surgery and treatment, the monkeys were processed either for biochemistry (choline acetyltransferase assay) or immunocytochemistry. In lesioned vehicle-treated animals, choline acetyltransferase activity significantly decreased by 28% in the cortex surrounding the injured area and by 31% in the ipsilateral nucleus basalis of Meynert when compared with values of sham-operated monkeys. These biochemical changes were fully prevented with the administration of nerve growth factor alone or in combination with the monosialoganglioside GM1. The morphometrical analysis revealed a significant shrinkage of cholinergic neurons (61 +/- 1.4% of sham-operated cell size) and loss of neuritic processes (59 +/- 10% of sham-operated values) within the intermediate nucleus basalis region of lesioned vehicle-treated animals. Although a protection of the cholinergic cell bodies within the nucleus basalis was found with both treatments, a significant recovery of the neuritic processes (84 +/- 7.2% of sham-operated values) was assessed only in the double-treated monkeys. These results indicate that the early administration of nerve growth factor alone or in combination with the monosialoganglioside GM1 induces a long-term protective effect on the nucleus basalis cholinergic neurons in cortical injured non-human primates.

Animals↗
PubMed1989

Repeated reserpine administration up-regulates the transduction mechanisms of D1 receptors without changing the density of [3H]SCH 23390 binding.

Behavioural studies have shown that stimulation of D1 receptors, which is uneffective in normal rats, induced strong hypermotility in rats pretreated with reserpine for 5 days. On this basis, we investigated D1 receptor plasticity using the 5-day treatment with reserpine (1 mg/kg; s.c.) as an experimental model. The function of striatal D1 receptors was determined both in binding studies with [3H]SCH 23390 and by measuring formation of cAMP in response to the selective agonist, SKF 82526. The results indicate that the responsiveness of adenylate cyclase (AC) to D1 receptor stimulation was markedly increased after reserpine administration, while no significant changes were found in [3H]SCH 23390 binding site density. Moreover, formation of cAMP after stimulation of Gs protein with GppNHp was markedly enhanced in dopamine (DA)-depleted rats; the responsiveness of AC to forskolin, which directly stimulates the AC catalytic unit, was not affected by reserpine administration. These data indicate that reserpine-induced D1 receptor up-regulation is apparently mediated by a marked enhancement of the coupling efficiency of Gs protein, suggesting that the D1 behavioral supersensitivity does not correlate with the density of D1 receptors, but is reflected by a selective up-regulation of their transduction mechanisms.

Adenylyl Cyclases↗
PubMed1988

Dopamine selectively inhibits angiotensin II-induced aldosterone secretion by interacting with D-2 receptors.

Aldosterone secretion is subject to both stimulatory and inhibitory controls. Angiotensin II (AII) is the primary stimulator of aldosterone production and an inhibitory role of dopamine (DA) has been suggested recently. In this study we investigated the interactions between DA and AII in the intracellular events leading to aldosterone secretion. By measuring aldosterone secretion and cyclic AMP (cAMP) formation in intact adrenal glomerulosa cells we show that AII induced a sustained stimulation of aldosterone secretion (EC50, 0.41 nM) and a rapid and transient increase in intracellular cAMP content (EC50, 4 nM). DA inhibited both aldosterone secretion (IC50, 300 nM) and cAMP formation (IC50, 100 nM) elicited by submaximal concentrations of AII; in contrast, DA did not attenuate either basal or adrenocorticotropic hormone-stimulated cell activity. The pharmacological characterization of DA effects with dopaminergic agonists and antagonists strongly indicated an involvement of D-2 receptors. Indeed, selective D-2 agonists were more effective than DA in inhibiting the glomerulosa cell responses to AII; in addition, the effects of DA on both aldosterone secretion and cAMP formation were prevented by D-2 antagonists, such as (-)-sulpiride and domperidone, but not by the selective D-1 antagonist SCH 23390. These data suggest a specific functional interaction between D-2 receptors apparently associated with inhibition of cAMP formation and AII in the regulation of aldosterone production.

Adrenal Cortex↗
PubMed1986

Characterization of dopamine receptors associated with aldosterone secretion in rat adrenal glomerulosa.

Dopamine (DA) may participate in the control of aldosterone secretion. We report that two different receptors for DA are present in rat adrenal glomerulosa: D-1, associated with stimulation of adenylate cyclase, and D-2, whose action inhibits adenylate cyclase. The adenylate cyclase system was stimulated by DA (EC50, 7.2 microM) and different DA agonists. When the D-1 receptor blocker SCH 23390 was added to the incubation medium, DA elicited a dose-dependent inhibition of adenylate cyclase (IC50, 10 microM); (-)sulpiride specifically blocked this effect. Furthermore, DA blocked angiotensin II-induced aldosterone release from glomerulosa slices in vitro. This effect was prevented by (-)sulpiride, but not by SCH 23390. The results suggest that the D-2 receptor acts to inhibit the cAMP-generating system and may be physiologically involved in the regulation of aldosterone secretion.

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-ben↗
PubMed1985

Identification of D-2 dopaminergic receptors in bovine adrenal cortex.

Dopamine receptors in bovine adrenal cortex have been studied by using 3H-(-)sulpiride as selective ligand. The specific binding is saturable and the Scatchard analysis reveals a single component with a Kd of 6.2 nM and a Bmax of 8 fmoles/mg protein. The characterization indicates that the binding is rapid, reversible, stereospecific, Na+ - and temperature- dependent. Moreover its pharmacological profile is superimposable to that of D-2 receptors in the striatum, thus suggesting that central and peripheral D-2 receptors are identical.

Adrenal Cortex↗
PubMedDate not supplied

Primate models of cholinergic dysfunction.

Neuropathological studies are currently providing extensive information upon which to base experimental models of neurodegenerative diseases. While it seems unlikely that a single model encompassing all aspects of degenerative dementia will be developed in the near future, models that are more restricted in their scope can provide useful data about processes which range from cellular to behavioral disturbances. In this article we present recent primate studies revealing that mature basal forebrain cholinergic neurons degenerate as a consequence of the removal of their target. Both fimbria fornix transection and cortical devascularization seem to be useful tools in the assessment of potential neurotrophic and neuroprotective properties of pharmacological agents.

Acetylcholinesterase↗